Acura Pharmaceuticals Announces Second Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acura Pharmaceuticals Announces Second Quarter 2014 Financial Results

PALATINE, IL--(Marketwired - Aug 4, 2014) -  Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2014.

The Company reported a net loss of $3.5 million for the second quarter 2014 or $0.07 per diluted share, compared to net loss of $3.1 million or $0.07 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $1.3 million in the second quarter 2014, compared to $0.8 million for the same period in 2013. Selling, marketing, general and administrative expenses were $1.9 million in the second quarter 2014, versus $2.0 million in the same period last year. Selling and marketing expenses primarily consist of advertising and marketing activities for NEXAFED®.

The Company reported a net loss of $7.6 million for the six months ended 2014 or $0.16 per diluted share, compared to net loss of $7.3 million or $0.16 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $2.7 million in the six months ended 2014, compared to $2.8 million for the same period in 2013. Selling, marketing, general and administrative expenses were $4.2 million in the six months ended 2014, versus $4.2 million in the same period last year. Selling and marketing expenses primarily consisted of advertising and marketing activities for NEXAFED®.

As of July 30, 2014, the Company had cash, cash equivalents and marketable securities of $16.5 million and $10.0 million in term debt financing.

We launched NEXAFED® commercially in mid-December 2012. Given the limited sales history of NEXAFED®, we could not reliably estimate expected returns of the product at the time of shipment. Accordingly, we have deferred recognition of revenue and the related cost of sales on selected product shipments of NEXAFED® until the right of return no longer exists or adequate history and information is available to estimate product returns. At June 30, 2014 we have deferred $0.3 million of revenue from shipments of NEXAFED®. During the second quarter 2014 we shipped $53 thousand of NEXAFED® and we recognized revenue of $34 thousand for shipments to customers where the right of return no longer existed either because a pricing allowance was accepted in exchange for forfeiting the right of return or because information became available on pharmacy's reorder activity with their drug wholesaler. We will continue to analyze information to assess the recognition of our revenue but also expect to continue the deferral of some revenue from NEXAFED® in the foreseeable future.

Conference Call Information Acura Pharmaceuticals, Inc. will host a conference call on Tuesday, August 5, 2014 at 8:30 a.m. ET to discuss the results.

To participate in the live conference call, please dial 1-888-505-4369 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 8612011 . A replay of the call will be available beginning August 6, 2014 at 11:30 a.m. ET and ending on August 22, 2014 on the company's website, and by dialing 1-888-203-1112 (U.S. and Canada). The replay participant code is 8612011 .

About Acura Pharmaceuticals Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved our oxycodone HCl immediate-release tablets which incorporate the AVERSION® Technology. The Company has a development pipeline of additional AVERSION® Technology products containing other opioids. 

In December 2012, the Company commenced commercialization of NEXAFED® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE® Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:

  • our ability to enter into a license agreement for our FDA approved AVERSION® oxycodone product;
  • our and our licensee's ability to successfully launch and commercialize our products and technologies including AVERSION® oxycodone and NEXAFED® Tablets;
  • the results of our meetings or discussions with the FDA relating to our AVERSION® hydrocodone/acetaminophen product;
  • whether we will conduct an additional intranasal abuse liability study on our AVERSION® hydrocodone/ acetaminophen product and whether the results of such study will support a claim of intranasal abuse deterrence;
  • our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
  • the market acceptance of and competitive environment for any of our products; 
  • the willingness of wholesalers and pharmacies to stock NEXAFED® Tablets;
  • expectations regarding potential market share for our products and the timing of first sales;
  • our ability to enter into additional license agreements for our AVERSION® Technology product candidates;
  • our exposure to product liability and other lawsuits in connection with the commercialization of our products;
  • the increasing cost of insurance and the availability of product liability insurance coverage;
  • the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
  • the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
  • the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet OTC Monograph standards as applicable;
  • the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
  • changes in regulatory requirements;
  • adverse safety findings relating to our product candidates;
  • whether the FDA will agree with our analysis of our clinical and laboratory studies;
  • whether further studies of our product candidates will be required to support FDA approval;
  • whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies; and
  • whether our AVERSION® product candidates will ultimately deter abuse in commercial settings and whether our IMPEDE ® Technology will disrupt the processing of pseudoephedrine into methamphetamine.

In some cases, you can identify forward-looking statements by terms such as "may," "will", "should," "could," "would," "expects," "plans," "anticipates," "believes," "indicates," "estimates," "projects," "predicts," "potential," and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. 

 
 
ACURA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
 
    (unaudited)   (audited)
    June 30,   December 31,
    2014   2013
Current assets   $ 18,733   $ 27,453
Property, plant and equipment, net     928     941
Other assets     199     236
Intangible asset     2,000     -
  Total assets   $ 21,860   $ 28,630
             
Current liabilities   $ 1,595   $ 820
Deferred revenue - current     307     287
Current maturities of long-term debt     477     -
Long-term debt, net of debt discount of $341 and $400     9,182     9,600
Stockholders' equity     10,299     17,923
  Total liabilities and stockholders' equity   $ 21,860   $ 28,630
               
   
   
ACURA PHARMACEUTICALS, INC.  
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)  
(in thousands, except per share data)  
   
    Unaudited     Unaudited  
    Three Months Ended June 30,     Six Months Ended June 30,  
    2014     2013     2014     2013  
Revenues:                                
  Royalty revenue   $ 1     $ 1     $ 4     $ 5  
  Product sales, net     34       -       73       -  
    Total revenues, net     35       1       77       5  
Operating expenses:                                
  Cost of sales (excluding inventory write-down)     42       -       80       -  
  Inventory write-down     68       361       201       361  
  Research and development     1,281       805       2,719       2,831  
  Selling, marketing, general and administrative     1,916       1,975       4,175       4,197  
  Total operating expenses     3,307       3,141       7,175       7,389  
  Operating loss     (3,272 )     (3,140 )     (7,098 )     (7,384 )
Non-operating income (expense):                                
  Investment income     53       71       97       81  
  Loss on sales of marketable securities     -       (7 )     (5 )     9  
  Interest expense     (302 )     -       (603 )     -  
  Total other income (expense)     (249 )     64       (511 )     90  
  Loss before income taxes     (3,521 )     (3,076 )     (7,609 )     (7,294 )
  Provision for income taxes     -       -       -       -  
  Net loss   $ (3,521 )   $ (3,076 )   $ (7,609 )   $ (7,294 )
Other comprehensive income:                                
  Unrealized gains (losses) on securities     21       (131 )     50       (79 )
  Total other comprehensive income (expense)     21       (131 )     50       (79 )
  Comprehensive loss   $ (3,500 )   $ (3,207 )   $ (7,559 )   $ (7,373 )
                                 
                                 
Loss per share:                                
  Basic   $ (0.07 )   $ (0.07 )   $ (0.16 )   $ (0.16 )
  Diluted   $ (0.07 )   $ (0.07 )   $ (0.16 )   $ (0.16 )
Weighted average shares outstanding:                                
  Basic     48,848       47,228       48,846       47,215  
  Diluted     48,848       47,228       48,846       47,215  
                                   

Contact: for Acura Investor Relations Email Contact 847-705-7709 for Acura Media Relations Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 15

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 88

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 0

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 16

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 0

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 107

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 0

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading

Top 5 Most Recently Viewed Articles

MindClay Launches Immersive Wellness Experience at Conference

Updated Category News Views 299

MindClay Introduces Unique Wellness Lounge MindClay Offering Attendees a First-of-its-Kind Immersive Wellness Space MindClay is set to host its innovative Interactive Museum Wellness Lounge at the upcoming Behavioral Health Tech Conference, a leading event for professionals in the field. This unique wellness space promises to immerse attendees in a revolutionary approach...

Continue Reading
Northern 3 VCT PLC Announces Share Repurchase Program Details

Updated Category News Views 148

Northern 3 VCT PLC's Recent Share Buyback Northern 3 VCT PLC is excited to share its recent activity regarding share repurchase. On July 2, 2025, the Company executed a buyback of 2,176,639 ordinary shares priced at 85.50p each, totaling approximately 1.44% of the overall issued share capital. Details of the Transaction This strategic move was made under the authority...

Continue Reading
Key Industry Leaders Unite on GS1 US Board to Innovate Supply Chains

Updated Category News Views 436

Major Appointments to the GS1 US Board of Governors In a significant development for the supply chain industry, four prominent leaders have been elected to the GS1 US Board of Governors. This newly formed board includes key executives from major companies like Kroger, Publix, Sysco, and Walmart, who will work together to enhance efficiency and transparency across various...

Continue Reading
FedTech Expands Footprint with New Boston Hub for Innovation

Updated Category News Views 334

FedTech's Strategic Expansion with New Boston Hub FedTech, a renowned venture accelerator focused on deep tech commercialization, is thrilled to announce the launch of its Boston office. This development signifies a bold move in FedTech's growth strategy and its dedication to nurturing innovation across the New England region. The office, located at 50 Milk Street, will...

Continue Reading
Revolutionizing Finance: Oracle AI Agents Enhance Efficiency

Updated Category News Views 227

Enhancing Finance with Oracle AI Agents New AI agents embedded in Oracle Fusion Cloud Applications assist finance professionals in boosting productivity, minimizing costs, and enhancing control measures. During the recent Oracle AI World event, Oracle revealed an innovative suite of AI agents designed to revolutionize traditional finance functions. By leveraging the...

Continue Reading